Ricevi le ultime notizie sulle azioni Helix BioPharma con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di HBPCF

Ultime notizie per

HELIX BIOPHARMA CORP by Helix Biopharma Corp.

Helix BioPharma Corp

Helix BioPharma

Helix BioPharma (HBPCF) Previsione

Notizie

Vendite allo scoperto

Rapporto azionario

Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.

Comments

Helix BioPharma Notizie sulle azioni

Notizie

Ultime notizie per

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO